Xintela AB. 556780-3480 (Lund). Översikt · Telefonnummer · Adresser · Styrelse och koncern · Verklig huvudman · Nyckeltal · Kreditupplysning. Nu kan du

Lund-based company Xintela is judged to have a large market potential in a number of areas, not least in Osteoarthritis with the company's

Xintela AB | 882 följare på LinkedIn. Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. The key to Xintela’s operations is the company’s patented marker technology XINMARK™. Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of The work has been carried out in collaboration with IVRS (In Vivo Research Services) in Lund. The results show that Xintela's targeting antibodies are a promising new strategy for the treatment of glioblastoma. Xintela has approved patents that protect integrin α10β1 antibodies for the treatment of CNS tumors including glioblastoma. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis.

Uppgifter om Xintela Ab Lund i Lund. Se telefonnummer, adress, hemsida, öppettider mm. Gratis årsredovisning. Vinstmarginalen för Xintela AB ligger på -670,0 % och placerar bolaget på plats 398 259 i Sverige av 648 647 aktiebolag och i kommunen på plats 4 794 av 10 Köp aktier i Xintela - enkelt och billigt hos Avanza Bank.

Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours.

Lund, Sverige, 19 augusti 2020 - Xintela informerar att bolaget utökar och förstärker ledningen med Peter Ekolind som COO (Chief Operating

• Sep 26, 2018. 5 0 Aktiedagen Lund 30 januari - Serstech. Aktiespararna.

2021-04-06

Katarina has a MSc in Biology (Chemistry branch, main topic Immunology) from Lund University in 1992. Katarina was employed by BioInvent Int AB in Lund in 1991. 1992-1998 she did her industrial PhD-program and was during that time employed by BioInvent Int AB and Dept of Immunotechnology, LTH. Xintela was founded in 2009 by Evy Lundgren-Åkerlund and is based on her research from Lund University and in the company Cartela. Xintela is headquartered at Medicon Village in Lund, Sweden. The company’slaboratories are on the premises, including the GMP facility.

Klicka här för att se 09.00 i Medicon Village, Scheeletorget 1, hus 601, i Lund. Information med Lund, Sweden, 17 March 2021 - Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company's stem cell Xintela AB. 556780-3480 (Lund). Översikt · Telefonnummer · Adresser · Styrelse och koncern · Verklig huvudman · Nyckeltal · Kreditupplysning.
Börja odla i januari

Värdering och villkor 1 day ago Galectin-3 is a carbohydrate binding protein which has important roles in cancer and immunity. Potent galectin-3 inhibitors have been synthesized, for experimental purposes and potential clinical use. As galectin-3 is implicated in both intra- and extracellular activities, permeability of galectin-3 … Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder är mycket stort: ledbroskskador och hjärntumörer.
Kontoutdrag

Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 Email: evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se About Xintela Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based …

I have created one of Europe's most modern air laboratories in Lund and another at the Technical University of Amberg-Weiden in Germany. Together with Lund University of Technology (LTH), and Royal Institute of Technology (KTH) in Stockholm the collaboration so far has generated seven publications, of which I have been co-authors of four of them. Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to Medicon Village; Scheelevägen 2; 223 81 Lund; Sweden. Xintela has 15 employees at their 1 location. See insights on Xintela including office locations, competitors, revenue, financials, Xintela has an office in Lund. Lund, Sweden, 17 March 2021 - Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company's stem cell XINTELA BUILDING OWN GMP-FACILITY FOR STEM CELL PRODUCTION.

Senaste nytt om Xintela aktie. Xintela komplett bolagsfakta från DI.se. Bolaget grundades under 2009 och har idag sitt huvudkontor i Lund. Verkställande

Bolagsform: Publikt aktiebolag. SNI-bransch: 72190 Andra naturvetenskapliga och tekniska FoU-institutioner. View the latest Xintela AB (XINT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Lund SN 223 81.

Xintela AB (via Public) / Skiljedom meddelad till Xintelas fördel; Xintela bbtu. Nulägesanalys Xintela - Integrins marking the future - BioStock; Xintela : Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder är mycket stort: ledbroskskador och hjärntumörer. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis.